Top 20 Global Pharmaceutical Companies 2026

This report forms part of the Ranking News Healthcare Ranking series, which evaluates hospitals, medical institutions, pharmaceutical organizations, medical technology companies, diagnostics providers, laboratories, precision medicine platforms, and healthcare systems across global healthcare markets.

Global pharmaceutical companies remain central to modern healthcare by discovering, developing, manufacturing, and commercializing medicines across major therapeutic areas such as oncology, immunology, cardiovascular disease, diabetes, obesity, vaccines, neuroscience, rare diseases, respiratory medicine, infectious disease, and specialty care. Their institutional relevance is determined not only by sales scale, but also by research productivity, regulatory capability, global access, manufacturing infrastructure, and long-term therapeutic leadership.

Unlike biotechnology companies focused on narrower scientific platforms, global pharmaceutical companies operate broad multinational systems that combine discovery research, clinical development, regulatory affairs, manufacturing, market access, pharmacovigilance, medical affairs, commercialization, and lifecycle management. These organizations shape treatment standards, fund large-scale clinical trials, support physician education, and influence healthcare spending patterns across developed and emerging markets.

The pharmaceutical industry is entering a period of strategic transition. Patent cliffs, biosimilar competition, drug-pricing pressure, geopolitical supply-chain risk, and regulatory scrutiny continue to challenge incumbent companies. At the same time, demand for innovative medicines remains strong, particularly in oncology, obesity, diabetes, immunology, rare disease, and advanced biologics. Industry rankings and forecasts highlight continued reshuffling among major pharmaceutical companies, with Eli Lilly’s rapid revenue growth in 2025 driven by GLP-1 medicines representing one of the most visible shifts in the sector.

This ranking identifies global pharmaceutical companies whose platforms demonstrate sustained relevance across drug discovery, commercial scale, therapeutic innovation, manufacturing capability, international reach, and long-term portfolio resilience. Rather than focusing only on one-year revenue, the objective is to recognize companies whose pharmaceutical businesses remain structurally important within global healthcare.

Market Overview

The global pharmaceutical market remains one of the most research-intensive and strategically important sectors in healthcare. Large pharmaceutical companies fund clinical trials across thousands of sites, manufacture complex medicines under strict regulatory standards, and commercialize products in markets with diverse pricing, reimbursement, and access systems.

The sector continues to be shaped by blockbuster therapies. Oncology remains a dominant growth area, with immunotherapies, targeted therapies, antibody-drug conjugates, radiopharmaceuticals, cell therapies, and companion diagnostics reshaping treatment pathways. Metabolic disease has also become one of the most important growth engines, with GLP-1 and incretin-based medicines transforming the commercial outlook for obesity and diabetes treatment.

The industry’s competitive structure is changing. Traditional large pharmaceutical companies such as Roche, Novartis, Merck & Co., Pfizer, Johnson & Johnson, Sanofi, GSK, and Bristol Myers Squibb remain highly influential, but companies with exceptional growth platforms such as Eli Lilly and Novo Nordisk have moved closer to the center of global pharmaceutical leadership. Fierce Pharma reported that Eli Lilly’s 2025 sales rose 45% to $65.2 billion, moving it into the third position among top biopharma companies by revenue.

At the same time, the industry faces a significant patent-expiry cycle. Several major companies must replace revenue from aging blockbusters through new launches, acquisitions, licensing deals, and pipeline execution. This has increased competition for promising biotechnology assets and therapeutic platforms.

China’s pharmaceutical and biotechnology sector is also becoming more important. Evaluate’s 2025 World Preview highlighted China’s rapid biopharma rise alongside steady global growth and a continuing boom in biologics, underscoring the increasing international relevance of Chinese-origin innovation and licensing activity.

Industry Trend — 2026

The global pharmaceutical industry in 2026 is shaped by five major trends: metabolic disease expansion, oncology innovation, patent cliff management, biologics growth, and more active business development.

First, obesity and diabetes have become major strategic battlegrounds. GLP-1 and incretin-based therapies have transformed investor expectations and pharmaceutical growth models. Eli Lilly and Novo Nordisk remain the category leaders, while other major companies are pursuing internal development, licensing, or acquisitions to gain exposure to metabolic disease.

Second, oncology continues to drive innovation and strategic investment. Merck’s Keytruda franchise, Roche’s oncology and diagnostics ecosystem, AstraZeneca’s oncology portfolio, Bristol Myers Squibb’s hematology and immuno-oncology base, and Johnson & Johnson’s oncology business remain important pillars of the sector. Antibody-drug conjugates, bispecific antibodies, radioligand therapies, and precision oncology are likely to remain major investment priorities.

Third, patent cliffs are forcing portfolio renewal. Several large pharmaceutical companies face pressure from loss of exclusivity on major products. The ability to replace mature revenue with new launches, lifecycle management, biosimilar defense, and acquisitions is becoming a defining measure of institutional resilience.

Fourth, biologics and specialty medicines continue to expand. Evaluate’s 2025 World Preview pointed to continuing global pharmaceutical growth and strength in biologics, reinforcing the importance of complex manufacturing, immunology, oncology, and specialty therapeutic platforms.

Fifth, business development remains central. Large pharmaceutical companies increasingly depend on partnerships, acquisitions, and licensing to access external innovation. The sector’s recovery in investor sentiment has been described as cautious, with M&A and R&D evidence remaining important to sustaining confidence.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, organizations considered for this ranking were evaluated based on the following eligibility conditions:

• Operates primarily as a global pharmaceutical or biopharmaceutical company
• Maintains substantial activity in prescription medicines, biologics, vaccines, specialty care, or advanced therapeutic development
• Demonstrates meaningful global scale through commercial operations, regulatory approvals, manufacturing capacity, and international market access
• Maintains a significant research and development platform, including clinical-stage pipeline assets or major therapeutic franchises
• Demonstrates relevance across patient care, physician practice, payer systems, drug development, and healthcare markets

Pure medical device companies, diagnostics-only companies, contract research organizations, generic-only manufacturers, single-product biotechnology companies, and early-stage biotechnology firms without broad commercial infrastructure were generally excluded.

Methodology — Ranking Factors

Organizations included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term market capitalization alone. Key factors considered include:

• Scale and durability of prescription pharmaceutical revenue
• Breadth and quality of therapeutic-area portfolio
• Strength of late-stage pipeline and new product launches
• Global regulatory, manufacturing, and commercialization capability
• Leadership in high-growth areas such as oncology, immunology, obesity, diabetes, rare disease, vaccines, and specialty care
• Ability to manage patent expiries, biosimilar competition, and pricing pressure
• Scientific reputation, clinical development capability, and business development execution
• Institutional resilience, geographic diversification, and long-term strategic relevance

The objective of the ranking is to identify pharmaceutical companies whose platforms maintain sustained relevance within the global healthcare ecosystem.

The Healthcare Ranking Top 20 Global Pharmaceutical Companies 2026 ranking evaluates multinational pharmaceutical and biopharmaceutical companies based on pharmaceutical scale, therapeutic leadership, innovation capacity, global reach, and long-term institutional resilience.

The ranking universe consisted of approximately 100 global pharmaceutical and biopharmaceutical companies, from which 20 organizations were selected for inclusion.

Tier classifications reflect relative institutional positioning within the global pharmaceutical company segment and do not represent clinical recommendations, investment recommendations, or drug-specific endorsements.

---

Tier I — Leading Global Pharmaceutical Companies

Eli Lilly

• Headquarters: Indianapolis, United States
• Founded: 1876
• Core focus: Diabetes, obesity, oncology, immunology, neuroscience

Eli Lilly has become one of the most strategically important pharmaceutical companies in the world, driven by its leadership in diabetes and obesity medicines, alongside growing activity in oncology, immunology, neuroscience, and rare disease. The company’s rise reflects one of the most significant industry shifts of the current decade: the transformation of metabolic disease from a mature therapeutic area into one of the largest growth markets in global pharmaceuticals.

Lilly’s strength lies in its high-growth incretin platform, particularly its diabetes and obesity medicines. The commercial momentum of these therapies has repositioned the company from a large U.S. pharmaceutical group into a global growth leader with extraordinary investor attention and therapeutic influence. Fierce Pharma reported that Lilly’s sales increased from $45 billion in 2024 to $65.2 billion in 2025, moving it sharply upward among the world’s largest biopharma companies.

Beyond metabolic disease, Lilly maintains important franchises in oncology, immunology, and neuroscience. Its broader strategy reflects a combination of internal discovery, clinical development execution, and selective external partnerships.

Lilly’s rapid growth, category leadership in obesity and diabetes, strong pipeline visibility, and expanding global pharmaceutical influence support its position as a Tier I global pharmaceutical company in 2026.

Roche

• Headquarters: Basel, Switzerland
• Founded: 1896
• Core focus: Oncology, immunology, neuroscience, ophthalmology, diagnostics-linked precision medicine

Roche remains one of the most important pharmaceutical companies globally, with deep institutional strength in oncology, immunology, neuroscience, ophthalmology, and precision medicine. Its pharmaceutical business is supported by one of the world’s strongest diagnostics platforms, giving Roche a differentiated position at the intersection of therapeutics, biomarkers, companion diagnostics, and personalized healthcare.

Roche’s historical leadership in oncology continues to shape its institutional identity. Although several older oncology blockbusters have faced biosimilar pressure, the company retains one of the broadest oncology research and development engines in the industry. Its capabilities in antibody engineering, targeted therapies, cancer immunology, hematology, and diagnostics-linked treatment selection remain strategically important.

The company also has meaningful exposure to ophthalmology, neuroscience, rare diseases, and immunology. Roche’s ability to combine pharmaceutical development with diagnostic infrastructure gives it an advantage in areas where biomarker-defined treatment and companion diagnostics are increasingly central to clinical practice.

Roche’s scientific depth, global commercial scale, diagnostics integration, and long-standing oncology leadership support its position as a Tier I global pharmaceutical company.

Novartis

• Headquarters: Basel, Switzerland
• Founded: 1996
• Core focus: Innovative medicines, oncology, immunology, neuroscience, cardiovascular, radioligand therapy

Novartis is one of the world’s leading innovative pharmaceutical companies, with a focused strategy around prescription medicines, specialty care, and advanced therapeutic platforms. Following its strategic simplification and separation from non-core businesses, Novartis has increasingly emphasized high-value innovative medicines in areas such as oncology, immunology, neuroscience, cardiovascular disease, and radioligand therapy.

The company’s strength lies in its balanced portfolio and scientific breadth. Novartis has major capabilities in small molecules, biologics, cell therapy, gene therapy-related areas, and radioligand therapy. Its cardiovascular and oncology franchises remain particularly important, while its immunology and neuroscience programs provide additional long-term growth opportunities.

Novartis is also strategically significant because of its role in radioligand therapy, a field that links targeted oncology treatment with nuclear medicine and precision diagnostics. This area may become increasingly important as cancer care moves toward more targeted and biologically specific treatment modalities.

Novartis’ global reach, focused innovative medicines strategy, therapeutic breadth, and investment in advanced treatment platforms support its position among the leading global pharmaceutical companies.

Merck & Co.

• Headquarters: Rahway, United States
• Founded: 1891
• Core focus: Oncology, vaccines, infectious disease, cardiometabolic medicine, animal health

Merck & Co. remains one of the most important pharmaceutical companies globally, anchored by its oncology leadership, vaccine portfolio, infectious disease expertise, and growing cardiometabolic and specialty medicine activity. Its position has been strongly shaped by Keytruda, one of the world’s most commercially significant oncology medicines.

Merck’s strength lies in oncology execution and clinical development scale. Keytruda has influenced treatment standards across multiple tumor types and has become central to modern immuno-oncology. Drug Discovery & Development described Merck as maintaining a top position in 2025, supported by continued Keytruda momentum and 2024 Keytruda sales of $29.5 billion.

The company also maintains important vaccine and infectious disease franchises, including HPV prevention and antiviral medicine. These areas give Merck a broader public-health and preventive-medicine profile than companies focused mainly on specialty therapeutics.

Merck’s key challenge is long-term portfolio transition as Keytruda faces future loss of exclusivity. Its ability to execute on oncology lifecycle management, business development, vaccines, and new therapeutic areas will determine its post-Keytruda resilience. Its current scale, oncology influence, vaccine strength, and R&D capability support its Tier I position.

Johnson & Johnson Innovative Medicine

• Headquarters: New Brunswick, United States
• Founded: 1886
• Core focus: Oncology, immunology, neuroscience, pulmonary hypertension, infectious disease

Johnson & Johnson Innovative Medicine remains one of the largest and most diversified pharmaceutical platforms globally. Following the separation of its consumer health business, Johnson & Johnson’s healthcare identity is increasingly centered on innovative medicines and medical technology, with pharmaceuticals remaining a core driver of institutional relevance.

The company’s pharmaceutical strength lies in oncology, immunology, neuroscience, pulmonary hypertension, and specialty medicine. Its oncology portfolio includes important assets in hematologic malignancies and solid tumors, while its immunology franchise has historically provided durable revenue and scientific credibility.

Johnson & Johnson’s scale, regulatory experience, manufacturing strength, and global commercialization infrastructure give it a strong position in complex pharmaceutical markets. The company also benefits from a diversified healthcare model that includes medical technology, although this ranking focuses on its pharmaceutical business.

Its combination of therapeutic breadth, global reach, institutional resilience, and strong specialty medicine franchises supports its position among the leading global pharmaceutical companies.

---

Tier II — Established Global Pharmaceutical Companies

(Alphabetical order)

AbbVie

• Headquarters: North Chicago, United States
• Founded: 2013
• Core focus: Immunology, oncology, neuroscience, aesthetics, specialty medicine

AbbVie is one of the most important specialty pharmaceutical companies globally, with major strength in immunology, oncology, neuroscience, and medical aesthetics. The company built its early identity around Humira and has since worked to transition toward newer immunology medicines, hematologic oncology assets, and neuroscience products.

AbbVie’s strength lies in commercial execution and lifecycle management. Managing the post-Humira transition has been one of the most important strategic challenges in global pharmaceuticals, and the company’s newer immunology portfolio is central to its long-term resilience.

The company also maintains a meaningful oncology franchise, particularly in hematology, and has expanded its neuroscience and aesthetics platforms through acquisition and internal development. AbbVie’s therapeutic focus, cash generation, commercial capability, and specialty care expertise support its position among established global pharmaceutical companies.

Amgen

• Headquarters: Thousand Oaks, United States
• Founded: 1980
• Core focus: Biologics, oncology, inflammation, cardiovascular disease, rare disease

Amgen is one of the world’s leading biotechnology-derived pharmaceutical companies and remains highly relevant within global pharmaceuticals because of its biologics expertise, manufacturing capabilities, and specialty medicine portfolio. The company has strong positions in oncology, inflammation, cardiovascular disease, nephrology, bone health, and rare disease.

Amgen’s strength lies in biologic drug development and manufacturing. It was one of the companies that helped define the modern biotechnology industry, and it continues to operate as a scaled global biopharmaceutical company with commercial infrastructure comparable to traditional large pharma.

The company’s acquisition of Horizon Therapeutics expanded its rare disease and specialty medicine exposure. Amgen is also strategically relevant in biosimilars, where biologic manufacturing expertise can support both innovation and competition.

Amgen’s biologics heritage, global commercial reach, specialty portfolio, and manufacturing capability support its inclusion among established global pharmaceutical companies.

AstraZeneca

• Headquarters: Cambridge, United Kingdom
• Founded: 1999
• Core focus: Oncology, cardiovascular, renal and metabolic disease, respiratory, immunology, rare disease

AstraZeneca has become one of the strongest global pharmaceutical companies of the past decade, supported by major growth in oncology, cardiovascular-renal-metabolic medicine, respiratory and immunology, and rare disease. The company’s strategic transformation has positioned it as one of the leading innovative medicine platforms globally.

AstraZeneca’s strength lies in therapeutic focus and pipeline execution. Its oncology portfolio has become particularly important, spanning targeted therapies, immuno-oncology, antibody-drug conjugates, hematology, and lung cancer treatment. Its cardiovascular, renal, and metabolic franchise provides additional scale and durability.

The company’s acquisition of Alexion expanded its rare disease capabilities, giving AstraZeneca a stronger position in high-value specialty medicine. Its global reach and strong presence in both developed and emerging markets further reinforce its institutional relevance.

AstraZeneca’s oncology growth, diversified specialty portfolio, international footprint, and pipeline execution support its position among established global pharmaceutical companies.

Bayer Pharmaceuticals

• Headquarters: Leverkusen, Germany
• Founded: 1863
• Core focus: Cardiovascular, ophthalmology, oncology, women’s health, radiology-linked medicine

Bayer Pharmaceuticals remains a major global pharmaceutical business within Bayer AG, with strengths in cardiovascular medicine, ophthalmology, women’s health, oncology, hematology, and specialty care. Although Bayer as a group has faced significant pressures from its agricultural business and debt profile, its pharmaceutical division remains a relevant global platform.

The company’s pharmaceutical portfolio includes important products in anticoagulation, ophthalmology, radiology-linked medicine, and women’s health. It has also pursued acquisitions and partnerships to strengthen its pipeline, including ophthalmology and cell and gene therapy-related areas.

Bayer’s challenge is portfolio renewal as several mature products face competitive pressure. Its ability to develop or acquire replacement growth assets will be important for its long-term positioning.

Bayer Pharmaceuticals’ global reach, therapeutic history, specialist franchises, and continued pipeline investment support its inclusion among established global pharmaceutical companies.

Boehringer Ingelheim

• Headquarters: Ingelheim am Rhein, Germany
• Founded: 1885
• Core focus: Cardiometabolic disease, respiratory medicine, oncology, immunology, animal health

Boehringer Ingelheim is one of the world’s largest privately held pharmaceutical companies and remains an important global player in cardiometabolic medicine, respiratory disease, immunology, oncology, and animal health. Its private ownership gives it a distinctive strategic profile compared with publicly listed pharmaceutical companies.

The company’s strength lies in long-term research commitment and therapeutic focus. Its cardiometabolic and respiratory franchises have been central to its pharmaceutical identity, while its pipeline increasingly includes oncology, immunology, and metabolic disease programs.

Boehringer Ingelheim’s private structure allows it to pursue longer-term investment without the same quarterly-market pressure faced by listed companies. This can be advantageous in research areas requiring patience and sustained development.

Its global footprint, family ownership, therapeutic expertise, and research-based pharmaceutical platform support its inclusion among established global pharmaceutical companies.

Bristol Myers Squibb

• Headquarters: Princeton, United States
• Founded: 1887
• Core focus: Oncology, hematology, immunology, cardiovascular disease, neuroscience

Bristol Myers Squibb is a major global pharmaceutical company with deep strength in oncology, hematology, immunology, cardiovascular disease, and specialty medicine. Its institutional identity has been shaped by immuno-oncology, hematologic malignancies, and high-value specialty medicines.

The company’s strength lies in its oncology and hematology portfolio. Its acquisition of Celgene gave it major assets in blood cancers and immunology, while its own legacy portfolio includes important oncology and cardiovascular therapies. Bristol Myers Squibb remains highly relevant in cancer treatment, especially in immuno-oncology and hematologic malignancies.

The company faces important patent and portfolio renewal challenges, requiring strong execution on newer launches and pipeline assets. Its ability to manage loss of exclusivity and build replacement growth will be central to long-term resilience.

Bristol Myers Squibb’s oncology heritage, hematology strength, specialty medicine focus, and global commercial infrastructure support its inclusion among established global pharmaceutical companies.

GSK

• Headquarters: London, United Kingdom
• Founded: 2000
• Core focus: Vaccines, infectious disease, respiratory, immunology, oncology

GSK is one of the world’s most important vaccine and specialty pharmaceutical companies. Following the separation of Haleon, GSK has sharpened its focus on vaccines, infectious disease, respiratory medicine, immunology, and oncology.

The company’s strength lies in vaccines and infectious disease. GSK has one of the most significant vaccine businesses globally, with capabilities across research, manufacturing, regulatory affairs, and global public-health access. Its respiratory and immunology franchises provide additional therapeutic depth.

GSK’s challenge is to strengthen its pipeline and expand beyond historical core areas while sustaining vaccine leadership. Its oncology and specialty medicine pipeline will be important to its long-term positioning.

GSK’s vaccine scale, global public-health relevance, infectious disease expertise, and focused biopharma strategy support its position among established global pharmaceutical companies.

Novo Nordisk

• Headquarters: Bagsværd, Denmark
• Founded: 1923
• Core focus: Diabetes, obesity, rare endocrine disease, hemophilia

Novo Nordisk has become one of the most strategically important pharmaceutical companies in the world because of its leadership in diabetes and obesity treatment. The company’s GLP-1 and incretin-based medicines have transformed both its commercial profile and the broader metabolic disease market.

Novo Nordisk’s strength lies in focused therapeutic excellence. Unlike more diversified pharmaceutical companies, Novo has built deep expertise in diabetes, obesity, and endocrine-related medicine. This specialization has allowed it to lead major shifts in metabolic care and establish one of the strongest commercial positions in modern pharmaceuticals.

The company remains in intense competition with Eli Lilly in obesity and diabetes. Recent reporting has highlighted the importance of oral GLP-1 medicines and the potential for obesity treatment revenues to continue expanding substantially through the next decade.

Novo Nordisk’s metabolic disease leadership, global reach, manufacturing scale, and scientific focus support its position among established global pharmaceutical companies, with Tier I potential depending on continued execution in the obesity market.

Pfizer

• Headquarters: New York, United States
• Founded: 1849
• Core focus: Vaccines, oncology, internal medicine, inflammation and immunology, rare disease

Pfizer remains one of the world’s largest and most globally recognized pharmaceutical companies, with major capabilities in vaccines, oncology, internal medicine, immunology, rare disease, and anti-infectives. Its recent history was heavily shaped by COVID-19 vaccine and antiviral revenues, but the company is now focused on rebuilding post-pandemic growth.

Pfizer’s strength lies in global scale, manufacturing infrastructure, regulatory capability, and commercial reach. The company has one of the broadest pharmaceutical operating platforms in the world and remains highly relevant across multiple therapeutic areas.

The company is actively shifting toward oncology and specialty medicine. Recent reporting noted that Pfizer’s first-quarter revenue rose 5% to $14.45 billion, supported by products including Padcev, Eliquis, oncology biosimilars, and Nurtec, while the company maintained full-year revenue guidance of $59.5 billion to $62.5 billion.

Pfizer’s challenge is to convert scale into sustainable post-COVID growth through pipeline execution, acquisitions, and new product launches. Its global infrastructure and therapeutic breadth support its inclusion among established global pharmaceutical companies.

Sanofi

• Headquarters: Paris, France
• Founded: 1973
• Core focus: Immunology, vaccines, rare disease, neurology, diabetes legacy products

Sanofi is a major global pharmaceutical company with important positions in immunology, vaccines, rare disease, and specialty medicine. The company has increasingly repositioned itself around high-value specialty care and immunology while maintaining one of the world’s largest vaccine businesses.

Sanofi’s strength lies in its immunology and vaccine platforms. Its immunology portfolio has become a major growth driver, while its vaccines business provides global public-health relevance and manufacturing scale. The company also maintains important rare disease and specialty franchises.

Sanofi’s strategic challenge is to continue strengthening its innovative medicine identity while managing legacy primary-care businesses and competitive pressure. Its investment in immunology, vaccines, and specialty care supports long-term relevance.

Sanofi’s global footprint, vaccine infrastructure, immunology growth, and rare disease capabilities support its position among established global pharmaceutical companies.

---

Tier III — Specialist Global Pharmaceutical Companies

(Alphabetical order)

• Astellas Pharma
• Daiichi Sankyo
• Gilead Sciences
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries

---

Remarks

Global pharmaceutical companies continue to serve as essential infrastructure for healthcare innovation, treatment access, clinical research, manufacturing, and therapeutic standard-setting. Their role extends beyond commercial drug sales into regulatory science, physician education, pharmacovigilance, public health, and long-term investment in biomedical research.

The organizations recognized in this ranking represent pharmaceutical companies whose platforms maintain sustained relevance across innovative medicines, specialty care, biologics, vaccines, oncology, metabolic disease, immunology, rare disease, and global market access. Tier classification reflects relative institutional positioning within the global pharmaceutical company sector rather than direct clinical quality rankings.

Tier classification reflects relative pharmaceutical scale, therapeutic breadth, research productivity, pipeline strength, global reach, commercial execution, patent-cliff resilience, and long-term strategic relevance. The ranking does not constitute a medical recommendation, patient referral guidance, investment recommendation, or endorsement of any specific medicine.

---

Recognition

Organizations included in the Top 20 Global Pharmaceutical Companies 2026 ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• institutional presentations
• academic and recruitment materials

Ranking inclusion is editorially determined and independent of licensing, advertising, or commercial participation. Recognition-materials licenses govern only the use of official Ranking News / Healthcare Ranking assets, approved wording, and related communications materials.

Licensing inquiries:
[email protected]